It wasn’t long ago that we published several articles urging investors into the neglected biotech industry. Now Sara Nunnally over at Taipan Publishing says Central and Eastern Europe is a hot region for the sector right now. Big pharma is also looking to enter the rapidly growing market for generic drugs. And a popular way to establish a foothold in the region is through acquisitions of local firms.

The coming together of nanotech and biotech could resurrect the pharmaceutical market, says Patrick Cox in Penny Sleuth.

By using nanotech structures to modify existing drugs, small-cap pharma companies can sidestep the hefty costs and risks of new drug approval. This has traditionally been a major barrier to entry for start-ups. More importantly, early research has shown the altered drugs to be extremely effective against a broad range of serious diseases.

As new ventures approach IPO, they will create great investment opportunities. More from Patrick…

Another strong play from medical stock expert Rob Fannon.

Rob says that although Big Pharma stocks are cheap right now – bellwether Pfizer (PFE) is cheaper than it’s ever been – drugmakers are racing off the side of a cliff.

This is because when patents expire drugmakers loose billions of dollars to generic manufacturers.

But biotech drugs can’t be copied easily. And the sector is in an uptrend. Rob recommends using a biotech ETF to play this trend.